1. Volume 10, Issue 6, Pages 581-588 (June 2009)
Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study 
Dr Bella Kaufman, MD, Prof Maureen Trudeau, MD, Prof Ahmad Awada, MD, Kimberly Blackwell, MD, Thomas Bachelot, MD, Vanessa Salazar, BS, Michelle DeSilvio, PhD, Ronald Westlund, MS, Tal Zaks, MD, Neil Spector, MD, Stephen Johnston, MD 
The Lancet Oncology 
Volume 10, Issue 6, Pages (June 2009)
DOI: /S (09)
Copyright © 2009 Elsevier Ltd Terms and Conditions

2. Figure 1 Study populations and design
*HER2-overexpressing (HER2+) patients had HER2 immunohistochemistry (IHC) 3+ or fluorescence in-situ hybridisation (FISH) amplified tumours. 15 patients from cohort A had tumours that were HER2 2+ without FISH amplification.
The Lancet Oncology  , DOI: ( /S (09) )
Copyright © 2009 Elsevier Ltd Terms and Conditions

3. Figure 2 Clinically evaluable skin disease
Before treatment with lapatinib (A) and response after 84 days (B) of lapatinib therapy.
The Lancet Oncology  , DOI: ( /S (09) )
Copyright © 2009 Elsevier Ltd Terms and Conditions

4. Figure 3
Kaplan-Meier estimates of investigator-assessed progression-free survival in the HER2+ positive population
The Lancet Oncology  , DOI: ( /S (09) )
Copyright © 2009 Elsevier Ltd Terms and Conditions

5. Figure 4
Kaplan-Meier estimates of overall survival since first dose of treatment in the HER2+ population
The Lancet Oncology  , DOI: ( /S (09) )
Copyright © 2009 Elsevier Ltd Terms and Conditions

6. Figure 5
Mean change from baseline in 33 patients with brief pain inventory (BPI)–short form pain scores
Error bars are 95% CI.
The Lancet Oncology  , DOI: ( /S (09) )
Copyright © 2009 Elsevier Ltd Terms and Conditions